Clinical trials: Adverse Reaction to Drug
Adverse Drug Reaction
Adverse Drug Reactions With Fatal Outcome
The purpose of this study is to determine the incidence of drug-related deaths in a university hospital during the year 2015
- Trial name
- NCT02838212
- Testing
- adverse drug reaction
- Volunteers
- 1,135 people
- Sponsor
- Germans Trias i Pujol Hospital
Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
To test the ability of palifermin (a recombinant human keratinocyte growth factor) to decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome-Toxic Epidermal…
- Trial name
- NCT02037347
- Testing
- Palifermin
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Brett King
Adverse Drug Reaction (ADR), Polypharmacy Patients
IPGx PILOT Whole Genome Sequencing Extension Cohort
The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make…
- Trial name
- NCT06766071
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Texas A&M University
Seizures
Pathogenesis of Adverse Drug Reactions
The purpose of the study is to examine the individual metabolic profiles of pediatric patients receiving carbamazepine or valproate therapy, in an attempt to determine identities of the reactive metabolites or, alternatively, the…
- Trial name
- NCT00224952
- Testing
- No intervention; Urine Collection
- Where
- 3 sites in United States
- Volunteers
- 274 people
- Sponsor
- Children's Mercy Hospital Kansas City
Graft vs Host Disease, Congenital Aniridia
Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation
The ARGOS-IO pressure sensor is intended to be implanted in the human eye in combination with Boston Keratoprosthesis (BKPro) surgery and to remain in place indefinitely.
- Conditions
- Graft vs Host Disease, Congenital Aniridia, Chemical Burns, Stevens-Johnson Syndrome
- Trial name
- NCT02945176
- Testing
- ARGOS-IO system
- Where
- 2 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Adverse Drug Reaction (ADR)
The INTEGRATE Study: Integrated Pharmacogenetics, TDM and Active Pharmacovigilance as Innovative Tools for the Optimisation and Appropriateness of Drug Therapy
The primary goal of this observational study is to evaluate the feasibility of implementing a multidisciplinary approach based on pharmacogenetics, TDM (Therapeutic Drug Monitoring) and MedReview into the clinical practice in…
- Trial name
- INTEGRATE (NCT06822959)
- Testing
- Pharmacogenetics, TDM and MedReview
- Where
- 2 sites in Italy
- Volunteers
- 450 people
- Sponsor
- Direzione centrale salute, politiche sociali e disabilità
Arthritis, Cancer
Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction
Immune checkpoint inhibitors (ICIs) might have high grade immune-related adverse events (irAEs) from rhumatologic, endocrinologic, cardiac or other system origin.
- Conditions
- Arthritis, Cancer, Cardiac Disease, Endocrine System Diseases
- Trial name
- CHIMeRA (NCT03492242)
- Testing
- Immune checkpoint inhibitor
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Kidney Impairment
Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy
This study is to investigate blood and urine kidney injury markers (especially Uromodulin) in pediatric cancer patients treated with nephrotoxic chemotherapy.
- Trial name
- Kid-MaCareOnco (NCT04308642)
- Testing
- blood test for renal biomarkers, urine test for renal biomarkers
- Where
- Switzerland
- Volunteers
- 6 people
- Sponsor
- University Hospital, Basel, Switzerland
Perioperative Complication, Hypersensitivity
Defining ENDOtypes in Perioperative Hypersensitivity by Extensive Cellular and Molecular PHENotyping (ENDOPHEN)
Perioperative Acute Hypersensitivity (PAH) is a systemic reaction that occurs rapidly following injection of a drug during anesthesia.The HSA-PA reaction must occur within a maximum of one hour after the induction of anesthesia…
- Trial name
- ENDOPHEN (NCT04006106)
- Where
- 7 sites in France
- Volunteers
- 103 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Adverse Drug Event
Adverse Drug Events at Emergency Department
Emergency departments (EDs) are a crucial element of the health care systems at interface between hospital and communities. The goals of the ED are to make an initial diagnosis and deliver urgent and critical care 24 hour per day…
- Trial name
- ADEsED (NCT03442010)
- Testing
- Detection of adverse drug events
- Where
- France
- Volunteers
- 13,453 people
- Sponsor
- University Hospital, Montpellier
Chronic Pain, Hypertension
Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction
The purpose of this study (PASSION study) is to monitor symptoms of chronic pain before and after 2 weeks of a standard drug commonly used to treat elevated blood pressure compared with 2 weeks of placebo (crossover design) so…
- Conditions
- Chronic Pain, Hypertension, Diuretics Drug Reactions, SCS
- Trial name
- PASSION (NCT04676399)
- Testing
- Hydrochlorothiazide 12.5mg
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Kansas Medical Center
Adverse Drug Related Events
Development of a Screening Strategy for Community-based Adverse Drug Related Events in the Emergency Department
Adverse Drug Related Events (ADREs) are a leading cause of Emergency Department (ED) visits in Canada. However emergency physicians recognize only half of all ADREs in patients presenting to the ED, missing opportunities to…
- Trial name
- NCT00727610
- Where
- 2 sites in Canada
- Volunteers
- 1,588 people
- Sponsor
- University of British Columbia
Drug Toxicity
Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects
To Evaluate the safety and tolerability after KD101 single oral dosing in healthy male subjects To Evaluate the pharmacokinetic property after KD101 single oral dosing in healthy male subjects To Evaluate the effect of food on…
- Trial name
- NCT01979380
- Testing
- KD101
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Cardiotoxicity, Thoracic Radiotherapy
Optimizing Radiation Dose and Utilizing Wearable Devices to Reduce Arrhythmia Risk in Patients Undergoing Thoracic Radiotherapy: A Prospective Cohort Study
This prospective observational cohort study aims to assess the risk of radiation-induced cardiotoxicity in patients undergoing thoracic radiotherapy by integrating real-time arrhythmia monitoring using wearable cardiac…
- Conditions
- Cardiotoxicity, Thoracic Radiotherapy, Wearable Electronic Devices, Thoracic Neoplasms
- Trial name
- NCT06897189
- Where
- South Korea
- Volunteers
- 111 people
- Sponsor
- Yonsei University
Neuroendocrine Tumors, Carcinoid Syndrome
A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
The purpose of the protocol is to to assess subject's overall satisfaction regarding control of diarrhea. The study aims to supplement results obtained through clinical trials with data obtained from a population of patients…
- Trial name
- SYMNET (NCT01234168)
- Where
- 57 sites in Czechia, France and 6 more
- Volunteers
- 340 people
- Sponsor
- Ipsen
Drug-Related Side Effects and Adverse Reaction, Digoxin Overdose
Introducing Electronic Alerts to Reduce Inappropriate Digoxin Prescribing in Older Adults
The intervention consists of introducing computerized alerts into the electronic medical record of the CSAPG (MIRA software), which are triggered when a physician prescribes digoxin at a dose higher than the recommended amount…
- Trial name
- Aldigo (NCT07008144)
- Testing
- Digoxin alarm
- Where
- 2 sites in Spain
- Volunteers
- 5,954 people
- Sponsor
- Consorci Sanitari de l'Alt Penedès i Garraf
Polypharmacy Patients
Assessment of a Novel Algorithm System for Polypharmacy Patient Medication Safety and Consultation
The aim of this study is to determine if insights based on the analysis of historical data of multidrug patients' electronic health records, by a novel system and algorithm, is noninferior to a clinical pharmacist analysis and…
- Trial name
- NCT05589870
- Testing
- Multi-drug analysis of polypharmacy treatment
- Where
- Israel
- Volunteers
- 91 people
- Sponsor
- MDI Health
Adverse Drug Reactions, Clinical Decision Support
Multi-Agent Collaborative ADR Prediction With Human-Machine Decision Comparison
This study develops a multi-agent collaborative prediction model to forecast adverse drug reactions using real-world clinical medical records.
- Trial name
- NCT07808866
- Testing
- Retrospective medical record data analysis only, no clinical intervention
- Where
- 2 sites in China
- Volunteers
- 20,000 people
- Sponsor
- Peking University Third Hospital
Adverse Reaction to Drug
Intensive Monitoring Scheme of Lidocaine Cataplasms
In this center, retrospective research methods are used to collect data. Patients who had used Lidocaine Cataplasms at least once were included consecutively.
- Trial name
- NCT05645302
- Testing
- Lidocaine Cataplasms
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Qianfoshan Hospital
Cardiovascular Complication, Cardiovascular Insufficiency
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care
Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer…
- Conditions
- Cardiovascular Complication, Cardiovascular Insufficiency, Cardiac Complication, Oncologic Complications
- Trial name
- NEOCARDIO (NCT03882580)
- Testing
- Anti-Cancer Agents
- Where
- 3 sites in France
- Volunteers
- 5,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere